Corporate News tagged:
GMP
Apr 09, 2026
REPROCELL USA Inaugurates GMP-Compliant Cell Culture Facility
REPROCELL USA has opened a new GMP-compliant cell culture facility to enhance regenerative medicine manufacturing and support global biopharmaceutical needs.
Oct 20, 2025
REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCs
REPROCELL and Histocell achieve GMP certification for clinical-grade iPSC manufacturing, advancing regenerative medicine and cell therapy production under EU regulations.
Jul 22, 2025
REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones
REPROCELL is pleased to announce the successful submittal of its StemRNA™ Clinical iPSC Seed Clones with the U.S. Food and Drug Administration (FDA) via a Type II Drug Master File (DMF).
May 05, 2025
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
May 30, 2024
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
Apr 18, 2024
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
REPROCELL announces the acquisition of a self-contained GMP system to expand our GMP capabilities.
Jan 31, 2024
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.
Jan 15, 2024
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
Sep 02, 2021
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.
Jun 29, 2021
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
Read more about REPROCELL's new Seed iPSC Manufacture Suite to provide supply for the increasing demand of iPSC-derived Master Cell Banks
May 13, 2019
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders.